evipedia.ai
← Back

Obicetrapib for Health & Longevity

Evidence Review created on 10/28/2026 using AI4L / Opus 5.5

Also known as: TA-8995, AMG 899, DEZ-001, Ubeslo

Motivation

Obicetrapib is a once-daily prescription tablet that blocks a blood protein which shuttles cholesterol between the particles circulating in the bloodstream. Blocking this protein is designed to lower the cholesterol carried by the particles that build up in artery walls. It draws interest from people focused on long-term health because the cholesterol in these particles is among the best-established modifiable drivers of heart attack and stroke, and because most comparable add-on options beyond standard cholesterol tablets are injections.

The drug belongs to a class whose earlier members were tested in large heart trials and never reached the market, which makes its history instructive. Obicetrapib was designed to avoid the problems of those predecessors and received its first approval, in the European Union, in 2026. Interest has since widened beyond the heart, because its largest cholesterol trial also measured blood markers of Alzheimer’s disease in people at high risk of heart disease.

This review examines what the evidence shows about obicetrapib’s effects on heart and blood vessel health and on brain health, what risks and open questions accompany its use, and how it is dosed and monitored, for health-focused adults considering it within a long-term prevention strategy.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary and reviews that discuss obicetrapib directly and in depth.

No content on obicetrapib was found from Rhonda Patrick, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; web and on-site searches returned nothing, likely because the drug was investigational until its September 2026 European approval, as reported by the developer (NewAmsterdam release; EMA Ubeslo opinion).

Grokipedia

  • Obicetrapib

    An AI-written overview of mechanism, phase 2–3 lipid results and the Alzheimer’s program; it predates the developer-reported September 2026 European approval (NewAmsterdam release; EMA Ubeslo opinion) and still calls the drug investigational.

Examine

No Examine article on obicetrapib exists. Examine.com does not typically cover prescription medications, and obicetrapib is a prescription drug.

ConsumerLab

No ConsumerLab article on obicetrapib exists. ConsumerLab does not typically cover prescription medications, and obicetrapib is a prescription drug.

Systematic Reviews

This section lists systematic reviews and meta-analyses of obicetrapib and of the CETP inhibitor class.

No systematic review addresses long-term risks such as macular degeneration; the reviewed safety data cover at most 52 weeks of treatment.

Mechanism of Action

CETP moves cholesteryl esters from HDL (high-density lipoprotein) to apoB-containing particles (apolipoprotein B, the structural protein on every artery-clogging particle), namely VLDL (very-low-density lipoprotein) and LDL (low-density lipoprotein). Blocking CETP keeps cholesterol in HDL, so HDL cholesterol (HDL-C) roughly doubles. Cholesterol-depleted VLDL and LDL are cleared faster: in a NewAmsterdam Pharma co-authored study in mice carrying human CETP, obicetrapib raised liver LDL-receptor (the hepatic uptake protein) expression and accelerated VLDL clearance (Inia 2026). The result is lower LDL cholesterol (LDL-C), non-HDL cholesterol, apoB and Lp(a) (lipoprotein(a), an inherited LDL-like particle).

Two mechanistic views compete. The original HDL-raising rationale collapsed when HDL-raising CETP inhibitors failed. The current view holds that benefit tracks the fall in apoB particles, which is smaller than the fall in LDL-C (Ference 2017). A third, untested hypothesis links remodeled HDL to brain cholesterol transport, of most interest for APOE4 carriers (people with the highest-risk Alzheimer’s variant of APOE, a cholesterol-transport gene).

Pharmacology (developer-authored studies):

  • Selectivity: highly selective; no off-target blood-pressure effect in pooled trials (Nelson 2026).
  • Half-life: about 131 hours at 10 mg (Nicholls 2024).
  • Distribution: less fat-soluble than anacetrapib; no adipose accumulation in monkeys (Nicholls 2024).
  • Metabolism: limited; mainly by CYP3A4 (the main drug-processing liver enzyme), less by other CYP enzymes, with most drug excreted unchanged in feces; no clinically relevant effect on atorvastatin (a statin, the standard cholesterol-lowering drug class) or rosuvastatin levels (Kastelein 2025).

Historical Context & Evolution

Obicetrapib originated as TA-8995 at Mitsubishi Tanabe, was developed by the Dutch company Dezima Pharma, later held by Amgen, and is now developed by NewAmsterdam Pharma with Menarini as European partner. Its intended use has always been lowering atherogenic (artery-clogging) lipids to prevent cardiovascular disease.

The class history shaped its design. Torcetrapib raised deaths and cardiovascular events alongside off-target rises in blood pressure and aldosterone (a salt-retaining hormone); the investigators called the mechanism unknown and could not rule out a class effect (Barter 2007). Dalcetrapib raised HDL-C without lowering LDL-C and showed no event benefit (Schwartz 2012). Evacetrapib lowered LDL-C yet was neutral over 26 months (Lincoff 2017). Anacetrapib reduced major coronary events by 9% over 4.1 years (Bowman 2017), widening to 12% with extended follow-up (Sammons 2022), but Merck chose not to file for approval (Merck release).

These results shifted the explanation: the failures did not refute CETP inhibition; they showed that HDL-C raising alone does not protect, while lowering apoB particles does. The developer-funded TULIP trial then showed TA-8995 lowered LDL-C up to 45% as monotherapy (Hovingh 2015). Interest in health optimization grew from genetic studies linking naturally low CETP activity to less cardiovascular disease and diabetes (Ference 2017; Chen 2026, developer co-authored), and from the Alzheimer’s-marker signal. After a positive opinion from the European Medicines Agency (EMA Ubeslo opinion), the European Commission approved obicetrapib in September 2026, as reported by the developer; the EMA page still shows only the opinion (NewAmsterdam release).

Expected Benefits

High 🟩 🟩 🟩

Lower LDL Cholesterol, Non-HDL Cholesterol and Apolipoprotein B

Alone or added to statin-based lipid therapy, obicetrapib 10 mg lowered LDL-C versus placebo in trials led by several research groups: Hovingh (Amsterdam; Hovingh 2015), Nicholls (Monash; Nicholls 2022, BROADWAY, BROOKLYN), Harada-Shiba (Osaka; Harada-Shiba 2024) and Sarraju and Nissen (Cleveland Clinic; Sarraju 2025). ApoB fell less than LDL-C. All trials were developer-funded: TULIP by Dezima Pharma, the later trials by NewAmsterdam Pharma.

Magnitude: In BROADWAY, LDL-C fell 32.6 percentage points more than placebo at day 84 (95% CI, the confidence interval or range of plausible true values, −35.8 to −29.5) (Nicholls 2025); in BROOKLYN (heterozygous familial hypercholesterolemia, inherited very high LDL-C), LDL-C fell 36.3% more than placebo (95% CI −42.2 to −30.4) and apoB 24.4% more (Nicholls 2026); a later author correction fixed two unrelated confidence-interval typographical errors (Nicholls 2026).

Medium 🟩 🟩

Fewer Major Cardiovascular Events ⚠️ Conflicted

A developer-authored pooled analysis of BROADWAY and BROOKLYN (2,884 patients, one year) found fewer coronary events, mainly after month six (Nicholls 2025). The broader composite including ischemic stroke (stroke from a blocked artery) was not statistically significant; the coronary-only composite reached significance narrowly. Class precedent is split: anacetrapib reduced coronary events (Bowman 2017), evacetrapib did not despite lowering LDL-C (Lincoff 2017). An independent editorial urged caution (Bittner 2025). Net: the direction favors benefit, but it is unconfirmed until the PREVAIL outcome trial reports.

Magnitude: Coronary death, heart attack, ischemic stroke or revascularization (stent or bypass): 3.9% versus 5.0%, HR (hazard ratio, the relative event rate over time) 0.77 (95% CI 0.54–1.11); coronary death, heart attack or revascularization: 3.2% versus 4.7%, HR 0.68 (95% CI 0.46–1.00) (Nicholls 2025).

Lower Risk of New-Onset Type 2 Diabetes

In pooled phase 3 data, obicetrapib did not raise HbA1c (glycated hemoglobin, a three-month blood-sugar average), and new diabetes was numerically less frequent (Brandts 2026); the safety composite of new or worsening diabetes was significantly lower (Nelson 2026). Mendelian randomization (a genetic natural experiment) predicts lower diabetes risk from CETP inhibition (Chen 2026). This contrasts with statins, which raised incident diabetes risk by 9% in a meta-analysis of randomized trials (Sattar 2010). All obicetrapib data come from one developer-funded group.

Magnitude: New-onset diabetes or worsening glycemic control: 32.9% versus 37.6%, RR (risk ratio, the relative risk) 0.88 (95% CI 0.79–0.97) (Nelson 2026); new-onset diabetes alone: 6.4% versus 8.5%, adjusted OR (odds ratio, a relative-odds measure) 0.69 (95% CI 0.47–1.03) (Brandts 2026).

Slower Decline in Kidney Function

A developer-funded, after-the-fact pooled analysis of BROADWAY and BROOKLYN found slightly slower decline in eGFR (estimated glomerular filtration rate, the kidneys’ filtering capacity) and nominally fewer renal composite events, with no change in urine albumin (Vogt 2026). The pooled safety analysis found fewer creatinine rises (Nelson 2026). An editorial by two co-authors of obicetrapib trial analyses called it a welcome signal but not yet a kidney story (Barkas 2026).

Magnitude: eGFR declined 0.67 mL/min/1.73 m² less than with placebo over one year (nominal P = 0.02, P being the chance probability of such a difference, “nominal” meaning unadjusted for multiple testing; no confidence interval reported in the abstract) (Vogt 2026); creatinine rise ≥0.3 mg/dL: 5.0% versus 7.3%, RR 0.69 (95% CI 0.51–0.93) (Nelson 2026).

Low 🟩

Lower Alzheimer’s Disease and Dementia Risk ⚠️ Conflicted

Obicetrapib slowed p-tau217 rises (unvalidated blood Alzheimer’s marker), most in APOE4 carriers (developer-authored; Davidson 2026); an uncontrolled pilot showed flat spinal-fluid cholesterol clearance (NCT05161715). Indirect genetics tied low CETP to less Lewy body dementia (protein-deposit dementia; developer co-authored, Schmidt 2024) but not Alzheimer’s (independent, Nordestgaard 2022). Net: plausible, clinically untested.

Magnitude: Plasma p-tau217 rose 2.84 percentage points less than with placebo over 12 months (2.09% versus 4.94%; P = 0.025; no confidence interval reported for the difference) (Davidson 2026).

Speculative 🟨

Lipoprotein(a) Lowering

Obicetrapib lowered Lp(a) about 37% in developer-authored pooled trials (Nicholls 2026). Lp(a) lowering is unvalidated: pelacarsen lowered Lp(a) without reducing events (Novartis release).

Modest Triglyceride Lowering ⚠️ Conflicted

Most meta-analyses of the obicetrapib trials found triglycerides about 7% lower than placebo (Araújo 2025; Kumar 2026); the largest found no difference (Bhatti 2025). Net: any lowering is small, with no validated link to events.

Improved HDL Particle Function

In a developer (Dezima Pharma) co-authored analysis, TA-8995 raised cholesterol efflux capacity (HDL’s ability to pull cholesterol from cells) by up to 38% (van Capelleveen 2016). Raising HDL-C alone has not prevented events (Schwartz 2012).

Coronary Plaque Regression

In mice carrying human CETP, obicetrapib plus ezetimibe on atorvastatin regressed established atherosclerosis (Inia 2026). No human imaging results exist yet; the basis is animal data only.

Benefit-Modifying Factors

  • APOE4 genotype: The p-tau217 effect was largest in APOE4 carriers and in APOE4/E4 homozygotes, with a 20.5% placebo-adjusted difference (Davidson 2026); genetic data also predict larger dementia-related effects in carriers (Schmidt 2024).
  • ADCY9 and CETP genetics: ADCY9 (a gene for a cell-signaling enzyme, proposed to modify CETP-inhibitor response) did not alter anacetrapib’s benefit (Hopewell 2019); no pharmacogenetic modifier of obicetrapib is known.
  • Baseline apoB versus LDL-C: Cardiovascular benefit tracks the apoB reduction more than the LDL-C reduction (Ference 2017), so the expected benefit is smaller than the LDL-C change suggests.
  • Baseline Lp(a): Absolute Lp(a) reductions were similar at baseline 50–150 nmol/L and ≥150 nmol/L (−36.3 versus −32.3 nmol/L) (Nicholls 2026).
  • Sex: Women made up 34% of BROADWAY and 54% of BROOKLYN participants (Nicholls 2025; Nicholls 2026); the trial abstracts report no sex-specific LDL-C results, so sex differences remain uncharacterized.
  • Ancestry: Japanese participants on statins showed a 45.8% median LDL-C reduction at 10 mg, similar to European cohorts (Harada-Shiba 2024).
  • Pre-existing conditions: In heterozygous familial hypercholesterolemia (inherited very high LDL-C), the LDL-C reduction was 36.3% (Nicholls 2026); the diabetes-risk direction was consistent in normoglycemia (normal blood sugar) and prediabetes (Brandts 2026).
  • Age: Phase 3 participants averaged 64–68 years (Nelson 2026; Sarraju 2025); no published analysis shows an age-dependent lipid response, and data in people over 80 are sparse.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse event has shown a statistically tested excess over placebo replicated in trials from independent research groups; the available excesses are small, untested numerical differences in registry tables.

Medium 🟥 🟥

Dizziness, Headache and Gastrointestinal Adverse Events

The EMA lists hypertension, dizziness, headache, diarrhoea and abdominal pain as the most common side effects (EMA Ubeslo opinion). Registry tables show small numerical excesses of dizziness and headache in BROADWAY (Nicholls group) and of headache and diarrhoea in TANDEM (Sarraju and Nissen group), not tested statistically. Overall adverse-event rates matched placebo over one year in pooled phase 3 data, mostly mild or moderate (Nelson 2026), although TANDEM’s 12-week rates were higher on active drug (Sarraju 2025).

Magnitude: BROADWAY dizziness 40/1,685 versus 15/843 and headache 43/1,685 versus 17/843 on placebo (NCT05142722); TANDEM monotherapy headache 6/102 versus 2/102 and diarrhoea 3/102 versus 0/102 (NCT06005597); any adverse event in TANDEM 54% (obicetrapib) versus 37% (placebo) (Sarraju 2025).

Low 🟥

Hypertension ⚠️ Conflicted

Hypertension was reported more often with obicetrapib in BROADWAY and TANDEM and is label-listed (EMA Ubeslo opinion), recalling torcetrapib (Barter 2007). Measured blood pressure did not differ from placebo in 2,880 pooled participants (Nelson 2026). Net: measured data outweigh reports; a meaningful rise is unlikely.

Magnitude: Hypertension reports: BROADWAY 82/1,685 versus 33/843 (NCT05142722), TANDEM 9/102 versus 3/102 (NCT06005597), BROOKLYN 14/234 versus 8/118 (NCT05425745); systolic blood pressure change at day 84 was 0.35 mmHg higher than placebo (95% CI −0.62 to 1.33) (Nelson 2026).

AMD (age-related macular degeneration, progressive central-vision loss) was more common with genetically low CETP activity, linked to higher HDL-C (Nordestgaard 2022); this is indirect genetic evidence. One-year trials recorded one case on obicetrapib, too short to exclude risk (Nelson 2026).

Magnitude: Genetic: HR 2.33 (95% CI 1.63–3.30) for AMD, scaled to a 17 mg/dL genetically lower non-HDL cholesterol (Nordestgaard 2022); trials: 1/1,919 on obicetrapib versus 0/961 on placebo (Nelson 2026).

Muscle Pain ⚠️ Conflicted

Myalgia (muscle pain) was more frequent with obicetrapib in BROOKLYN (NCT05425745) but stayed below the 2% reporting threshold in both arms of the larger BROADWAY (NCT05142722). Creatine kinase (a muscle-damage enzyme) elevations were not increased in pooled data (Nelson 2026). Net: no consistent muscle signal.

Magnitude: BROOKLYN myalgia 10/234 versus 1/118 on placebo (NCT05425745); pooled creatine kinase >5× upper limit of normal 0.4% versus 0.7% on placebo, RR 0.57 (95% CI 0.21–1.57) (Nelson 2026).

Speculative 🟨

Unknown Long-Term and Rare Effects

Published placebo-controlled exposure is one year in about 1,900 people (Nelson 2026). Anacetrapib, a different compound, showed no non-vascular harm over 6.3 years (Sammons 2022). The basis is absent long-term data.

Altered Transport of Fat-Soluble Antioxidants

HDL carries carotenoids such as lutein to the retina, and CETP inhibition remodels HDL. Effects on antioxidant delivery are untested; the basis is mechanistic only.

Risk-Modifying Factors

  • Genetic macular-degeneration risk: Carriers of high-risk CFH (complement factor H, an immune-regulating gene) or ARMS2 (a gene for a retinal protein that helps regulate complement immune activity) variants have higher baseline AMD risk; any CETP-related AMD effect could matter more (inferred, not studied).
  • Baseline blood pressure: People with uncontrolled hypertension have least margin for any blood-pressure effect; measured pooled data showed no rise (Nelson 2026).
  • Baseline retinal status: Existing drusen (yellow retinal deposits) or early AMD mark the group in which the genetic AMD signal (Nordestgaard 2022) would be most consequential.
  • Sex and reproduction: A pharmacokinetic study with a combined oral contraceptive (NCT06250205) completed in 2024 without posted results; no pregnancy safety data exist, and no sex-specific adverse-event analysis has been published (36% of pooled participants were women, Nelson 2026).
  • Liver disease: A moderate hepatic impairment pharmacokinetic study (NCT06048302) completed in 2024 without posted results; pooled trials showed no hepatic signal (Nelson 2026).
  • Kidney disease: eGFR decline was slower, not faster, on obicetrapib (Vogt 2026); severe kidney disease was not well represented.
  • Age: AMD incidence rises steeply with age, so older adults carry the most exposure to the genetic AMD signal; phase 3 participants averaged 64 years (Nelson 2026).

Key Interactions & Contraindications

Documented interactions:

  • Statins (atorvastatin, rosuvastatin): No clinically relevant pharmacokinetic interaction; atorvastatin exposure rose 9–10% (Kastelein 2025). Consequence: additive LDL-C lowering, up to 51% on high-intensity statins (Nicholls 2022); no dose adjustment needed.
  • Ezetimibe: Co-administration produced additive LDL-C lowering (48.6% versus placebo as a fixed-dose combination), with adverse-event rates similar to either drug alone (Sarraju 2025). Consequence: larger LDL-C drop; a lipid recheck at 4–8 weeks is common practice.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • PCSK9 inhibitors (drugs blocking proprotein convertase subtilisin/kexin type 9, an LDL-receptor-degrading enzyme; evolocumab, alirocumab) and bempedoic acid: Additive LDL-C lowering through increased LDL-receptor activity; consequence: very low LDL-C; a lipid recheck after adding is common practice.
  • Red yeast rice (monacolin K, chemically lovastatin): Additive LDL-C lowering through HMG-CoA reductase (cholesterol-synthesis enzyme) inhibition; consequence: larger LDL-C drop plus the statin-like muscle effects of red yeast rice itself; a lipid recheck and creatine kinase testing if muscle pain appears are common practice.
  • Berberine: Additive LDL-C lowering through LDL-receptor upregulation; consequence: larger LDL-C drop; a lipid recheck after starting is common practice.
  • Plant sterols/stanols and psyllium (over-the-counter cholesterol products): Additive LDL-C lowering through reduced intestinal cholesterol absorption; consequence: modestly larger LDL-C drop.
  • Strong CYP3A4 inhibitors (ketoconazole, clarithromycin) and inducers (rifampin, St John’s wort): Obicetrapib’s limited metabolism runs mainly through CYP3A4 (Kastelein 2025), so inhibitors may raise and inducers lower its levels; consequence: higher exposure or weaker LDL-C lowering; a lipid recheck after changes is common practice.
  • Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen) and oral decongestants (pseudoephedrine): Additive blood-pressure raising (sodium retention, vasoconstriction) on top of obicetrapib’s hypertension reports; consequence: higher blood pressure, which home readings during regular use can detect.
  • Lutein and zeaxanthin supplements: HDL transports these carotenoids to the retina, and CETP inhibition remodels HDL; consequence: unknown change in retinal antioxidant delivery.

Populations who should avoid Obicetrapib:

  • Children and adolescents: The European indication is limited to adults (EMA Ubeslo opinion).
  • Pregnancy and breastfeeding: Inferred from the absence of human reproductive safety data and cholesterol’s role in fetal development; no human data.
  • Existing intermediate or advanced AMD: Inferred from the genetic association of low CETP activity with AMD (Nordestgaard 2022); no trial data in this group.
  • Severe hepatic impairment (Child-Pugh Class C, the most severe liver-function category): Inferred from hepatic drug handling and unpublished hepatic impairment data limited to moderate impairment (NCT06048302); no human data in severe impairment.

Risk Mitigation Strategies

Doses, timings and thresholds below follow common practice unless cited.

  • Baseline retinal exam: A dilated eye exam or optical coherence tomography (retinal scan) before starting and every 1–2 years mitigates undetected progression of AMD, the main genetically suggested risk (Nordestgaard 2022).
  • Home blood pressure log: Readings for one week before starting, then weekly for the first three months, mitigate an unnoticed rise from the hypertension reported in trials.
  • Symptom review for dizziness and headache: A check at 2–4 weeks identifies the label-listed dizziness, headache and gastrointestinal effects (EMA Ubeslo opinion) early, when stopping resolves them as the drug clears.
  • Creatine kinase if muscle pain appears: Testing when new muscle pain occurs separates true muscle injury from nonspecific aches, mitigating overlooked myalgia, especially when combined with statins or red yeast rice.
  • Pregnancy avoidance: Effective contraception during use and for about four weeks after stopping (time to near-complete clearance, Nicholls 2024) mitigates unknown fetal risk.

Therapeutic Protocol

Parameters other than dose (timing, titration, monitoring intervals) reflect common practice unless cited.

  • Standard dose: 10 mg once daily, the dose selected for phase 3 development (Nicholls 2024) and tested in BROADWAY (Nicholls 2025), and approved in Europe, as reported by the developer (NewAmsterdam release; EMA Ubeslo opinion).
  • Fixed-dose combination: Obicetrapib 10 mg plus ezetimibe 10 mg in one tablet (Evlarco), taken together once daily (Sarraju 2025; EMA Evlarco opinion).
  • Lower doses: 2.5 and 5 mg lowered LDL-C less than 10 mg (Harada-Shiba 2024); they are not approved, as the product is available only as 10 mg tablets (EMA Ubeslo opinion; NewAmsterdam release).
  • Alternative regimens: Statin plus ezetimibe, bempedoic acid, the oral PCSK9 inhibitor enlicitide (US-approved 2026; FDA novel approvals 2026), PCSK9 antibody injections and inclisiran injections are competing LDL-lowering options, chosen by tolerance, access and cost.
  • Who popularized it: Developers John Kastelein and Michael Davidson (NewAmsterdam Pharma) led the clinical program; Peter Attia brought it to longevity audiences (Attia podcast).
  • Time of day: Any consistent time; a high-fat meal raised exposure 1.6-fold, judged clinically irrelevant (Nicholls 2024).
  • Half-life: About 131 hours, so steady state takes roughly four weeks and missed doses matter little (Nicholls 2024).
  • Single versus split dosing: A single daily dose; the long half-life gives no reason to split.
  • Genetic factors: APOE4 carriers showed the largest p-tau217 effect (Davidson 2026); no genotype changes the dose.
  • Sex: The same 10 mg dose was used for women and men; no sex-specific dosing exists.
  • Age: The same dose was used across adult ages; older adults may prioritize baseline retinal and blood-pressure checks.
  • Baseline biomarkers: Higher baseline LDL-C and apoB leave more room for absolute reduction; very low baseline apoB limits expected gain (Ference 2017).
  • Pre-existing conditions: Familial hypercholesterolemia (Nicholls 2026), statin intolerance (Sarraju 2025) and diabetes (35.8% of pooled phase 3 participants; Nelson 2026) were all studied at 10 mg.

Discontinuation & Cycling

  • Lifelong intent: LDL-C lowering works through continuous exposure, and the European indication is lipid-lowering treatment as an adjunct to diet (EMA Ubeslo opinion); benefit depends on sustained use. With the fixed-dose combination, both agents stop together.
  • Withdrawal effects: None reported; plasma levels fell 92% by four weeks after stopping (Nicholls 2024), and lipids are expected to return toward baseline.
  • Tapering: Not required; the long half-life produces a natural taper over several weeks.
  • Cycling: No rationale exists for cycling; cardiovascular risk tracks cumulative apoB exposure, so interruptions forfeit benefit.

Sourcing and Quality

  • Approved products: In the European Union, obicetrapib is a prescription medicine approved as Ubeslo (10 mg) and Evlarco (10 mg with ezetimibe 10 mg), commercialized by Menarini, per the developer (the EMA page shows only the opinion) (NewAmsterdam release; EMA Ubeslo opinion).
  • Formulation: Film-coated tablets containing obicetrapib hemicalcium, the salt form listed by the European Medicines Agency (EMA Ubeslo opinion).
  • United States: Not approved; the 2026 novel-approval list of the US Food and Drug Administration (FDA) has no obicetrapib entry (FDA novel approvals 2026), and the developer calls the European decision the first approval worldwide (NewAmsterdam release); outside trials, no legitimate supply exists.
  • Unregulated “research chemical” sellers: Purity, identity and dose of such material are unverified; pharmacy-dispensed product is the only quality-controlled source.
  • Compounding pharmacies and third-party testing: Not applicable; the patented molecule is not compounded, and regulated pharmacy supply replaces supplement-style third-party testing.

Practical Considerations

  • Time to effect: LDL-C reduction is near maximal by 8–12 weeks (Nicholls 2022; Nicholls 2025); the pooled event reduction emerged only after six months (Nicholls 2025).
  • Pitfall – LDL-C calculation: The Friedewald equation underestimated LDL-C at low LDL-C with high triglycerides during CETP inhibition; the Martin/Hopkins equation was most accurate (NewAmsterdam co-authored; Martin 2023).
  • Pitfall – reading HDL-C as benefit: HDL-C roughly doubles, but HDL-C raising itself has not prevented events (Schwartz 2012); apoB is the more informative response marker.
  • Regulatory status: Approved by the European Commission on 21 September 2026 for hypercholesterolaemia (reported by NewAmsterdam; EMA page not yet updated) (NewAmsterdam release; EMA Ubeslo opinion). Not approved by the FDA (FDA novel approvals 2026).
  • Off-label use: The European indication covers adults not at LDL-C goal on maximum tolerated statin, or statin-intolerant (EMA Ubeslo opinion); use purely for longevity at normal LDL-C is off-label.
  • Cost and payer incentives: Pricing is set country by country; payers have an incentive to favor generic statins and ezetimibe over a new branded drug, a potential structural bias in access rules, guideline formation and research funding.

Interaction with Foundational Habits

  • Sleep: No interaction (none). Trials reported no sleep-related signal; the dizziness and headache occasionally reported are unlikely to affect sleep, and dosing time can be chosen freely.
  • Nutrition: Potentiating. A diet low in saturated fat and rich in soluble fiber lowers LDL-C through separate mechanisms, adding to the drug’s effect. Food raises exposure 1.6-fold, a difference judged clinically irrelevant (Nicholls 2024); carotenoid-rich leafy greens supply the lutein that bears on the eye question.
  • Exercise: No interaction known (none). Pooled trials showed no increase in creatine kinase (Nelson 2026), so no muscle-damage concern for training; endurance exercise independently improves triglycerides and fitness-related cardiovascular risk.
  • Stress management: Indirect. No cortisol data exist; because chronic stress raises blood pressure and hypertension was reported in trials, stress reduction and home blood-pressure tracking complement each other during the first months.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes reference points: a lipid panel with apoB and non-HDL cholesterol, a one-time Lp(a) measurement, HbA1c, creatinine with eGFR, liver enzymes, a week of home blood-pressure readings, and a dilated retinal exam or retinal scan. LDL-C is best reported by the Martin/Hopkins equation or measured directly, because the Friedewald estimate can mislead during CETP inhibition (Martin 2023).

Ongoing monitoring follows this cadence: lipids, apoB and blood pressure at 4–8 weeks, then every 6–12 months; HbA1c, eGFR and liver enzymes every 6–12 months; creatine kinase only if muscle symptoms appear; retinal examination every 1–2 years. Success is defined by apoB and LDL-C reaching the chosen target without a sustained blood-pressure rise or new retinal change.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
LDL-C <55 mg/dL for very high cardiovascular risk (ESC/EAS 2019 guideline) Expected change: main efficacy marker ESC/EAS (European Society of Cardiology/European Atherosclerosis Society) guideline (Mach 2020); its panel included obicetrapib trial investigators; members’ income is not tied to obicetrapib. Conventional laboratory reference range: <100 mg/dL. Martin/Hopkins or direct LDL-C is more accurate during CETP inhibition (Martin 2023); fasting is optional
ApoB <65 mg/dL for very high cardiovascular risk (ESC/EAS 2019 guideline) Expected change: best marker of atherogenic particle number Mach 2020; panel included obicetrapib trial investigators; members’ income is not tied to obicetrapib. Conventional laboratory reference ranges vary, commonly up to about 100–130 mg/dL. The fall is smaller than that of LDL-C (Ference 2017)
Non-HDL cholesterol <85 mg/dL for very high cardiovascular risk (ESC/EAS 2019 guideline) Expected change: total atherogenic cholesterol Mach 2020; panel included obicetrapib trial investigators; members’ income is not tied to obicetrapib. Conventional laboratory reference range: <130 mg/dL. Calculated from a standard panel
Lp(a) <75 nmol/L (<30 mg/dL) (standard reference range); the relevant measure is change from own baseline Expected change: falls about 35–45% One baseline value suffices for risk; event benefit of lowering is unproven (Novartis release). Units (nmol/L versus mg/dL) are not interchangeable, so comparisons need the same unit
HDL-C ≥40 mg/dL in men, ≥50 mg/dL in women (standard reference range); roughly a doubling from own baseline is typical Expected change: confirms drug exposure and adherence Rise does not itself indicate benefit (Schwartz 2012); a missing rise suggests non-adherence
HbA1c 4.0–5.6% (standard reference range) Expected change: may improve; also a safety check Fasting not required; fasting glucose is the usual paired test. New or worsening diabetes was less frequent in pooled trials (Nelson 2026)
Creatinine / eGFR ≥60 mL/min/1.73 m² (standard reference range) Safety check; a modest favorable change is possible Strenuous exercise or a large meat meal within the prior 24 hours can raise creatinine. Decline was slower on obicetrapib in pooled trials (Vogt 2026)
ALT / AST ALT 7–56 U/L; AST 8–48 U/L (standard reference ranges) Safety check: a sustained rise changes use ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are liver enzymes; no hepatic signal in pooled trials (Nelson 2026)
Creatine kinase About 30–200 U/L (standard reference range) Safety check: tested if muscle pain appears Intense exercise within the prior 48 hours raises it independently

Qualitative markers:

  • Dizziness or headache, especially in the first weeks
  • Bowel changes or abdominal pain
  • New muscle pain or weakness
  • Vision changes: central blurring, distorted straight lines or reduced color contrast
  • Symptoms of high blood pressure, such as morning headaches

Emerging Research

  • PREVAIL cardiovascular outcome trial: 9,541 patients with atherosclerotic disease, obicetrapib 10 mg versus placebo, primary endpoint major cardiovascular events (NCT05202509); interim analysis planned late 2026, result expected early 2027 (NewAmsterdam release). Positive: event benefit confirmed. Null: lipid effects would not translate into protection.
  • REMBRANDT coronary plaque trial: Phase 3, 300 planned (323 enrolled per NewAmsterdam release), obicetrapib-ezetimibe versus placebo, primary endpoint non-calcified plaque volume by CCTA (coronary computed tomography angiography) at 18 months (NCT06305559). Positive: human plaque regression shown. Null: weakens the mechanistic bridge to fewer events.
  • SPINOZA preclinical Alzheimer’s trial: Phase 2, 400 adults with preclinical Alzheimer’s disease, primary endpoint p-tau217 change at 52 weeks (NCT07794670). Positive: replicates the biomarker signal in a dedicated population. Null: undermines the brain-health rationale.
  • RUBENS diabetes and metabolic syndrome (a cluster of abdominal obesity, high blood pressure, blood sugar and blood fats) trial: Phase 3, 300 participants, LDL-C change at day 84 for obicetrapib alone and with ezetimibe (NCT07219602). Positive: confirms efficacy in metabolic disease. Null: questions benefit in this growing group.
  • VINCENT Lp(a) trial: Phase 2, 69 participants with elevated Lp(a), obicetrapib then obicetrapib plus evolocumab (NCT06496243). Positive: defines additive Lp(a) lowering. Null: limits Lp(a) as a selling point, already uncertain after pelacarsen’s outcome result.
  • MEDICI head-to-head trial: Phase 3, 426 participants, obicetrapib versus bempedoic acid on LDL-C at 12 weeks (NCT07614958). Positive: superior oral non-statin option. Null: comparable alternatives remain equally reasonable.
  • VERMEER antioxidant and retina trial: Phase 2, 100 healthy volunteers, antioxidant levels in HDL and retinal tissue over four months (NCT06982508); still registered as recruiting. Positive (no reduction): eases the AMD concern. Null or reduction: strengthens it.
  • Completed early Alzheimer’s pilot: Open-label study in 13 APOE4 carriers (NCT05161715), completed 2023; registry results posted 2024 show plasma apolipoprotein A-I +37.5% but cerebrospinal-fluid apolipoprotein A-I −8.4% and cholesterol efflux +1.9% at 24 weeks (no control group); not published in a journal.
  • Macular degeneration evidence gap: The genetic AMD signal (Nordestgaard 2022) has not been tested with retinal endpoints in multi-year trials; PREVAIL safety data could strengthen or weaken it.
  • ApoB-based benefit expectations: Genetic analyses predict benefit proportional to apoB lowering (Ference 2017); PREVAIL will test whether obicetrapib’s event reduction matches that prediction.

Conclusion

Obicetrapib is a once-daily tablet that blocks a cholesterol-transfer protein, and it is the first drug of its class to win approval, in Europe in 2026. For health-focused adults whose cholesterol remains above target despite existing treatment, or who cannot tolerate standard cholesterol tablets, it offers a well-documented further drop in that cholesterol and in the particle count that best tracks risk, in tablet form rather than by injection.

Whether this translates into fewer heart attacks and strokes is not yet established. Early combined results from two trials point toward fewer heart attacks and related events, but a related drug lowered cholesterol without preventing events, and the dedicated outcome trial has not reported. Hints of lower diabetes risk, slower kidney decline and slower rises in an Alzheimer’s blood marker are intriguing but rest on limited or indirect evidence, and lowering an inherited cholesterol particle has not yet proven protective on its own.

Over the short term, side-effect rates resemble those of an inactive tablet, with dizziness, headache, digestive side effects and reports of raised blood pressure, while measured blood pressure has stayed flat. Genetic studies raise an unresolved question about an age-related eye disease that erodes central vision, and experience beyond one year remains thin.

Almost all clinical evidence comes from trials funded and largely authored by the developer, a conflict of interest that matters most for the outcome, kidney and brain findings. The overall picture is a strong cholesterol-lowering effect with an unproven long-term payoff.

Top - Benefits - Risks - Protocol